Renal Afferents by unknown
HYPERTENSION AND THE BRAIN (S STOCKER, SECTION EDITOR)
Renal Afferents
Alissa A. Frame1 & Casey Y. Carmichael1 & Richard D. Wainford1
Published online: 5 September 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Purpose of Review The etiology of hypertension, a critical
public health issue affecting one in three US adults, involves
the integration of the actions of multiple organ systems, in-
cluding the renal sympathetic nerves. The renal sympathetic
nerves, which are comprised of both afferent (sensory input)
and efferent (sympathetic outflow) arms, have emerged as a
major potential therapeutic target to treat hypertension and
disease states exhibiting excess renal sympathetic activity.
Recent Findings This review highlights recent advances in
both clinical and basic science that have provided new insight
into the distribution, function, and reinnervation of the renal
sympathetic nerves, with a focus on the renal afferent nerves,
in hypertension and hypertension-evoked disease states in-
cluding salt-sensitive hypertension, obesity-induced hyperten-
sion, and chronic kidney disease.
Summary Increased understanding of the differential role of
the renal afferent versus efferent nerves in the pathophysiolo-
gy of hypertension has the potential to identify novel targets
and refine therapeutic interventions designed to treat
hypertension.
Keywords Renal afferent nerves . Renal efferent nerves .
Hypertension . Radiofrequency ablation . Renal denervation .
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Introduction
Hypertension, which affects one third of the US adult popu-
lation and approximately 20% of adults worldwide, is a major
risk factor for adverse cardiovascular events—significantly
contributing to the epidemic of cardiovascular and kidney
disease, stroke, premature death, and disability [1].
Hypertension is a complex multifactorial disease involving
the integration of multiple regulatory systems and our under-
standing of the pathogenesis of this disease state remains in-
complete. Recent studies have explored the renal sympathetic
nerve-mediated mechanisms, both afferent and efferent nerve
based, in the long-term regulation of blood pressure as in-
creasing basic science and clinical evidence implicates the
renal nerves as a contributor to the pathophysiology of hyper-
tension [2–4]. Removal or interruption of the afferent and
efferent renal sympathetic nerves, which are located together
in the adventitia of the renal arteries, has been shown to reduce
blood pressure through multiple mechanisms. Reduction in
efferent renal nerve traffic to the kidney prevents sympathetic
nervous system-mediated (1) increased activity of the renin-
angiotensin-aldosterone system, (2) renal sodium reabsorp-
tion, and (3) reduced renal blood flow [5]. In contrast, removal
of afferent renal nerve traffic impacts the reno-renal reflexes to
modulate central sympathetic outflow to peripheral organs
(e.g., kidneys, heart) and the vasculature. The sensory renal
afferent nerves, located predominantly in the renal pelvis [5],
are chemo- and mechanosensitive and upon activation can
elicit either (1) an inhibitory reno-renal reflex to evoke renal
sympathoinhibition [5, 6] or (2) an excitatory reno-renal reflex
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to evoke sympathoexcitation [6–8]. Highlighting the potential
importance of the renal sympathetic nerves in regulating blood
pressure, it has been suggested that more than 50 % of clinical
hypertension cases can be categorized as neurogenic essential
hypertension and feature impaired regulation of the sympa-
thetic nervous system [9]. Therefore, a more complete under-
standing of the role(s) of the afferent renal nerves, which have
a profound impact on central sympathetic outflow, in both
health and disease will potentially reveal novel targets and
treatment paradigms for hypertension. The purpose of this
review is to highlight recent advancements in our understand-
ing of the actions of the afferent renal nerves in the etiology
and pathogenesis of hypertension.
Catheter-Based Radiofrequency Renal Denervation
The use of catheter-based radiofrequency renal denervation
(RFRD), which interrupts both the afferent and efferent renal
nerves, as an interventional approach to treat hypertension has
been under investigation in multiple clinical trials for the past
several years. The SYMPLICITY HTN-1 and HTN-2 trials
reported the blood pressure-lowering effects of RFRD are
sustained for at least a 36-month period in relatively small
populations with severe treatment resistant hypertension [4,
10]. In contrast, the SYMPLICITYHTN-3 trial failed to show
a significant reduction in systolic blood pressure between
sham and RFRD groups 6 months post treatment [11],
highlighting the pressing need to deepen our understanding
of the roles of the afferent and efferent nerves in blood pres-
sure regulation. The SYMPLICITY HTN-3 trial has several
advantages over SYMPLICITY HTN-1 and HTN-2, includ-
ing a larger sample size, inclusion of a control sham proce-
dure, and a single-blinded experimental design. This raises the
possibility, which remains to be fully investigated, that the
long-term antihypertensive effects observed in the highly con-
trolled small-scale HTN-1 and HTN-2 trials may not be repro-
ducible in the general population. The issues relating to the
design and conductance of SYMPLICITY HTN-3 are beyond
the scope of this review—however, the effectiveness of the
RFRD procedures conducted in this study have significant
implications for the reported negative outcome. In this study,
on average, operators performed approximately 3 RFRD pro-
cedures without previous experience. This raises the signifi-
cant issue that lack of operator experience may have impacted
the results through incomplete denervation [12], a profound
issue given the lack of a standardized accepted test for the
effective destruction of the renal sympathetic nerves during
the procedure [13]. Furthermore, the DENERHTN trial, in
which RFRD plus a standardized stepped-care antihyperten-
sive treatment (SSAHT) decreased blood pressure more than
identical SSAHT alone, highlights the potential importance
and clinical applicability of RFRD as a therapeutic approach
[14••]. Ultimately, the interpretation of conflicting data from
clinical RFRD trials is complicated by the current absence of a
clinical test confirming the effective destruction of the renal
sympathetic nerves [13], and the degree of denervation re-
quired for therapeutic benefit in humans has not been
investigated.
Subsequent post hoc analysis of the SYMPLICITY HTN-3
trial has revealed important predictors of the blood pressure
response to RFRD which are likely to guide future investiga-
tions pursuing RFRD. Supporting the impact of patient med-
ication, as revealed in DENERHTN, aldosterone antagonist
use and non-use of vasodilators was a positive predictor of
RFRD success. Highlighting the pivotal role of how RFRD
is performed, these analyses revealed that a higher number of
radiofrequency ablations and RFRD delivered in a four-
quadrant pattern resulted in greater blood pressure reduction
[15•]. Two recent basic science studies have suggested that
modifications to the RFRD technique may improve efficacy
of the procedure. An elegant study performed in swine con-
ducted RFRD at three sites, near the ostium, in the main renal
artery near the bifurcation, and in the renal artery extrarenal
branches [16]. This study revealed the greatest reduction in
renal NE content was observed following RFRD in the
extrarenal arterial branches, a result that may reflect that this
location had the greatest density of renal nerves and the
greatest number of nerves in proximity to the lumen. A second
study conducted in dogs suggests that electrical stimulation of
the renal nerves, which evoked rapid changes in blood pres-
sure via central mechanisms, could represent a response that
could (1) identify the sites at which RFRD should be applied
and (2) be applied post RFRD to confirm efficacy of RFRD
[17••]. The validation of such a test is critical given the con-
flicting results of clinical RFRD trials and the observation that
a threshold of 90 % surgical renal denervation is required for
therapeutic benefit in animal models. At present it remains
unknown if more extensive RFRD of both the afferent and
efferent renal nerves and conductance of RFRD closer to the
kidney would result in more profound and consistent reduc-
tions in blood pressure. However, increased ablation sites or
increased energy frequency may evoke adverse effects not
observed under the current treatment protocol.
Renal Afferent and Efferent Nerve Distribution
and Reinnervation
The unmet need to better understand the physiology and anat-
omy of the renal sympathetic nerves and characterize the im-
pact of reinnervation post renal sympathetic nerve denervation
has led to several recent advances. A pioneering study con-
ducted in human autopsy subjects has shed new insight into
the anatomical distribution of the peri-arterial sympathetic re-
nal nerves located around the renal arteries [18]. This
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important study has revealed the anatomical distribution of the
renal nerves with a clear predominance of efferent versus af-
ferent nerve fibers and a decreasing presence of nerve fibers
from proximal to distal locations. Further, it was revealed that
within the distal regions (closest to the kidney), approximately
75 % of nerves are within 3 mm of the lumen, well within the
range of RFRD, which generates lesions of 4-mm diameter.
This suggests, as confirmed in a recent study conducted in
swine [16], that greater RFRD efficacy is likely when ablation
is conducted distally. Significantly, there was a difference ob-
served in renal nerve anatomy between normotensive versus
hypertensive subjects [18]. Two recent postmortem studies
support the hypothesis that in renal arteries with a large diam-
eter, renal nerve innervation is located further from the lumen,
which would reduce efficacy of RFRD and require greater
energy to produce significant ablation [19, 20]. The most re-
cent study [20] again supports the growing body of evidence
that the nerves are closer to the lumen in distal versus proximal
regions. This increased knowledge of renal nerve anatomy
will facilitate the refinement of current RFRD techniques,
with future directions including RFRD at more distal locations
and the adoption of a circumferential versus interrupted pat-
tern of ablation.
As it is not yet possible to assess reinnervation in human
subjects, a recent study conducted in normal Sprague-Dawley
rats utilized immunohistochemistry to investigate the time
course of renal reinnervation following surgical renal dener-
vation (RDN) [21]. In this study, peptide markers of both
afferent (substance P, calcitonin gene-related peptide) and ef-
ferent renal nerves (tyrosine hydroxylase, neuropeptide Y)
were restored 9–12 weeks post denervation. While these re-
sults should be confirmed using neuroanatomic markers to
verify the renal nerves as the source of the peptide markers,
this study raises the intriguing, yet to be addressed, question of
the functionality of the renal nerves following reinnervation in
this setting. A recent study in sheep partially addresses this
question by reporting that physiological responses to electrical
stimulation of the renal nerves are abolished immediately fol-
lowing RFRD in normotensive sheep but are restored at 5.5
and 11 months post RFRD. Importantly, these functional
changes are mirrored by the initial loss and subsequent resto-
ration of peptide markers of both afferent and efferent renal
nerves [22•]. Given the prolonged time frame of blood pres-
sure reduction post RFRD in human patients [4, 10], it is
highly likely that reinnervation has occurred without altering
the blood pressure phenotype. A significant and clinically rel-
evant question that remains unanswered is the functional sta-
tus of reinnervated nerves. Are the responses of the regrown
renal afferent nerves restored to normal in hypertensive ani-
mals or human subjects? Do regrown efferent nerves exhibit
normal regulation of sodium, renin, and renal hemodynamics?
Is there resetting of central nervous system mechanisms to
alter sympathetic outflow following RFRD?
Selective Renal Afferent Nerve Ablation
As previously discussed, surgical denervation and RFRD
removes the influence of both the afferent and efferent renal
sympathetic nerves—preventing the dissection of the individ-
ual actions of each arm. To facilitate the dissection of the role
of the renal afferent nerves, a novel method of selective abla-
tion of the renal afferent nerves by periaxonal application of
capsaicin has been developed in rats [23••]. This technique
selectively disrupts the renal afferent but not efferent renal
n e r v e s ( c o n f i r m e d p h a r m a c o l o g i c a l l y a n d
immunohistochemically), and supports recent studies on the
timeline of nerve regrowth, with afferent nerve reinnervation
suggested by the return of calcitonin gene-related peptide to
50 % of control levels within 7 weeks [23••]. However, the
time course of renal afferent nerve reinnervation requires fur-
ther investigation using neuroanatomical markers. These stud-
ies provide a new opportunity to examine the contribution of
the afferent renal nerves to multiple pathophysiological states.
Studies conducted using this technique suggest that the renal
afferent nerves are not essential to maintain normotension and
sodium balance in response to graded chronic alterations in
dietary sodium intake Sprague-Dawley rats. In contrast, the
renal afferent nerves play a role in the full development of
deoxy-corticosterone acetate-salt hypertension, with afferent
nerve ablation attenuating the observed hypertension by ap-
proximately 50 % [23••]. Extending investigations into the
role(s) of the renal sympathetic nerves in the development of
salt-sensitive hypertension, bilateral RDN conducted after the
establishment of hypertension reduces blood pressure in the
Dahl salt-sensitive (DSS) rat model [24]. A follow-up study
confirmed that bilateral RDN reduces blood pressure in
established short- and long-term DSS hypertension, and that
this response reflects an efferent renal nerve effect as renal
afferent nerve removal did not reduce blood pressure in hy-
pertensive DSS rats [25]. These new studies, extending find-
ings from the 1980s in which bilateral RDN prior to high salt
intake did not attenuate the development of DSS hyperten-
sion, suggest that the underlying cause of hypertension, and
the role of the renal nerves, may be different during develop-
ing versus established hypertension.
Bilateral RDN, but not selective renal afferent nerve
ablation, attenuates angiotensin-II hypertension and in-
flammation, further suggesting that the differential impact
of the afferent versus efferent nerves on blood pressure
regulation may depend on the underlying cause of hyper-
tension [26]. The differential responses observed to RDN
and selective renal afferent nerve ablation in these recent
studies highlight the unique mechanistic information that
can be derived using the novel renal afferent ablation
technique, and future studies are required to assess the
roles of the renal afferent nerves in other hypertension
paradigms (e .g . , obes i ty- induced hyper tens ion ,
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neurogenic hypertension) and settings involving excess
sympathetic nerve activity (e.g., heart failure).
The Renal Afferent Nerves and Heart Failure
In the pathophysiology of heart failure, which can arise as a
result of hypertension-evoked heart disease, reduced cardiac
output and organ perfusion evokes multiple compensatory
mechanisms including activation of the sympathetic nervous
system. Increased efferent renal nerve activity, which evokes
renal sodium and water retention, renin release, and renal va-
soconstriction, is widely accepted to contribute to renal dys-
function in heart failure [27]. Further, recent studies in con-
scious sheep have identified the hypothalamic paraventricular
nucleus (PVN) as a central site that regulates increased renal
sympathetic outflow in heart failure [28]. In contrast, the
role(s) of the renal afferent nerves in the pathophysiology of
heart failure remains largely unexplored. Recent studies from
the Patel laboratory reported that there is increased activity of
RVLM-projecting PVN neurons in a rat model of chronic
heart failure [29]. Advancing this work, the same authors have
revealed that there is a neural connection from the PVN to the
RVLM that is activated by direct stimulation of the renal af-
ferent nerves [30•]. These data illustrate that afferent output
from the kidney is integrated with PVN preautonomic neu-
rons, significantly enhancing our mechanistic understanding
of the actions of the renal afferent nerves. This raises the
untested hypothesis that this novel renal afferent nerve acti-
vated neural circuit may play a critical role in the modulation
of sympathetic outflow in heart failure. It has been previously
established that the inhibitory mechanoreceptor reno-renal re-
flex is attenuated in heart failure [5]. However, the modulation
of the excitatory chemo-reflex in heart failure remains to be
established.
The impact of RDN on heart failure has been investigated
in multiple experimental models and in clinical studies in the
last several years. Post-myocardial infarction bilateral RDN
improves cardiac function in rats [31]. In rat models of heart
failure, bilateral RDN has been demonstrated to (1) attenuate
renal sodium reabsorption via a Na-K-2Cl dependent pathway
when RDN is performed prior to the establishment of heart
failure [32] and (2) improve cardiac function when RDN is
conducted during established heart failure [33]. In larger ani-
mal models of pacing-induced heart failure, bilateral RDN
prior to heart failure induction improved cardiac function
[34]. Suggesting the potential importance of bilateral RDN,
unilateral RDN did not improve cardiac function despite im-
proving cardiac autonomic balance via reductions in sympa-
thetic outflow in a rabbit pacing-induced heart failure model
[35]. In clinical trials in heart failure patients, RDN has been
demonstrated to be safe and efficacious and to increase walk-
ing distance [36], reduce left ventricular mass, and increase
ejection fraction [37, 38]. Collectively, these basic science and
clinical data suggest that RDN represents a therapeutic ap-
proach that would benefit heart failure patients.
Ventricular arrhythmias (VAs) are the major cause of sud-
den cardiac death in most forms of heart disease, including
hypertension-evoked heart disease [39]. It is well established
that increased sympathetic activity contributes to the develop-
ment and maintenance of VAs [40]. As such, recent studies
have investigated the utility of RFRD, which reduces sympa-
thetic activity, as a therapeutic approach to treat VAs. A piv-
otal role of the renal nerves in triggering VAs has been dem-
onstrated by evidence that electrical activation of the renal
sympathetic nerves promotes acute ischemia-induced VAs
through actions on the left stellate ganglion in a canine model
[41]. Further evidence generated in canine models supports a
role of the renal nerves in VAs, as RDN reduces VAs during
acute myocardial ischemia [42] and pacing-induced heart fail-
ure [34]. These studies suggest the mechanism underlying the
attenuation of VAs following RDN is a correction of ventric-
ular electrophysiological remodeling [34, 42]. The utility of
RDN in the clinical setting as an approach to treat VAs has
been explored in small populations with cardiac myopathy
and treatment-resistant ventricular tachycardia. These studies
have demonstrated (1) the safety of this procedure in this
patient population and (2) a profound reduction in VAs
[43–45]. Collectively, these data suggest that RDN represents
a potential approach to treat heart failure and VAs, and that
patients with identified sympathetic over activity are likely to
benefit most from this approach. However, further studies to
elucidate the likely differential effects of the afferent versus
efferent renal nerves in these clinical paradigms would pro-
vide additional mechanistic insight.
The Renal Afferent Nerves and Obesity-Induced
Hypertension
It is well established that increased sympathetic nervous sys-
tem activity contributes to the development and maintenance
of obesity-induced hypertension [46]. Of relevance to this
review is the pivotal role of the renal sympathetic nerves in
obesity-evoked hypertension. Bilateral RDN restored blood
pressure to normotensive levels in dogs with established
obesity-induced hypertension [47]. Significantly, confirming
the validity of a catheter-based approach, RFRD lowered
blood pressure in a dog model of obesity-induced hyperten-
sion despite only partial nerve ablation [48]. Based on seminal
work done in the 1990s in the laboratory of Dr. Hall, it is
thought that the major benefits of RDN in obesity-induced
hypertension are mediated via efferent renal nerve removal
versus interruption of afferent renal nerve pathways. Recent
findings in obese normotensive Sprague-Dawley rats imply
that neural signals originating from the kidney (presumably
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renal afferent nerve mediated) contribute to autonomic dys-
regulation (i.e., impaired arterial and cardiopulmonary
baroreflexes) in obesity [49].While a direct role of the afferent
renal nerves in mediating signal transduction from the kidney
in this paradigm requires further confirmation (e.g., selective
renal afferent nerve ablation), these studies challenge the lack
of a role of the renal afferent nerves in this pathophysiological
condition and suggest reassessment of the impact of the renal
afferent nerves in obesity-induced hypertension may yield
new insight.
The Renal Afferent Nerves and Chronic Kidney
Disease
Chronic kidney disease (CKD), which affects approximately
8 % of the world’s population over the age of 30, can be
initiated or exacerbated by hypertension. CKD exhibits the
hallmarks of sympathetic activation and baroreflex dysfunc-
tion that increases with disease progression [50]. Recent stud-
ies in a rodent model of cisplatin-induced renal failure have
reported inappropriate activation of renal afferent sensory
nerves, which impairs the regulation of renal sympathetic out-
flow. The authors report that high and low pressure baroreflex
regulation of renal sympathetic nerve activity and volume
expansion evoked renal sympathoinhibition is attenuated in
cisplatin-induced renal failure—responses that are restored
following acute bilateral RDN [6, 51]. These data suggest that
in CKD, renal afferent sensory nerve activation via inflamma-
tory pathways may evoke an excitatory reno-renal reflex to
enhance renal ef ferent nerve ac t iv i ty and renal
sympathoexcitation. Extending these data to a clinical setting,
patients with end-stage renal disease on dialysis exhibit a
marked increase in renal nerve density versus control subjects.
Additionally, this study reported increased renal nerve endings
present in patients with hypertensive arteriolar damage [52•].
This study did not differentiate between the presence of renal
afferent versus efferent fibers but suggests RFRD may be a
suitable therapeutic approach in the setting of CKD.
Conclusion
Over the last several years, our understanding of the locations
and function of the renal afferent and efferent nerves has dra-
matically increased through novel discoveries in both basic
science and clinical arenas. These findings have solidified
the renal sympathetic nerves as a predominant mechanism in
multiple hypertensive disease states to drive elevations in both
sympathetic outflow and blood pressure. The advances
outlined in this review have revealed an increasingly impor-
tant role of the renal sympathetic nerves in blood pressure
regulation and sympathetic outflow. These findings suggest
that the site at which RFRD is performed may significantly
impact the outcome in terms of blood pressure, and that the
renal afferent nerves may function differently depending on
the underlying causes of hypertension. The next few years will
provide further delineation of the role(s) of renal afferent
nerve pathways and will potentially identify cross talk of these
pathways across hypertension disease states. We speculate
that current and future identification of the function and anat-
omy of the renal afferent and efferent sympathetic nerves will
generate new therapeutic targets and refinements to current
catheter-based renal denervation approaches that will have
broad applications in the treatment of human hypertension.
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